Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOE ε 4 carriers

Journal of Alzheimer's Disease

Volumn 46, Issue 2, 2015, Pages 525-533

  Starks, Erika J ^a   Patrick O'grady, J ^a   Hoscheidt, Siobhan M ^a   Racine, Annie M ^a   Carlsson, Cynthia M ^a,b   Zetterberg, Henrik ^c,d   Blennow, Kaj ^c,e   Okonkwo, Ozioma C ^a   Puglielli, Luigi ^a,b   Asthana, Sanjay ^a,b   Dowling, N Maritza ^a   Gleason, Carey E ^a,b   Anderson, Rozalyn M ^b   Davenport Sis, Nancy J ^a   Derungs, Le Ann M ^a   Sager, Mark A ^a   Johnson, Sterling C ^a,b   Bendlin, Barbara B ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

Author keywords

Alzheimer's disease; apolipoprotein 4; cerebrospinal fluid; glucose; insulin; insulin resistance; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CARRIER; FEMALE; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN INTERACTION; REGISTER; AMYLOID PLAQUE; CEREBROSPINAL FLUID; COMPLICATION; GENETICS; MIDDLE AGED; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; WISCONSIN;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; REGRESSION ANALYSIS; TAU PROTEINS; WISCONSIN;

EID: 84930453413     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150072     Document Type: Article

References (52)

1. Rawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, Griswold M, Gottesman RF, Wagenknecht LE, Windham BG, Selvin E (2014) Diabetes in midlife and cognitive change over 20 years: A cohort study. Ann Intern Med 161, 785-793
2. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, BretelerMM(1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942
3. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904
4. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-Amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167
5. Kim B, Backus C, Oh S, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150, 5294-5301
6. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438
7. Frolich L, Blum-Degen D, Riederer P, Hoyer S (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. AnnNY Acad Sci 893, 290-293
8. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, De La Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J Alzheimers Dis 7, 63-80
9. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481
10. LiuY, Liu F, Grundke-Iqbal I, Iqbal K, GongCX(2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111, 242-249
11. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB (2014) Insulin resistance predicts brain amyloid deposition in late middle-Aged adults. Alzheimers Dement, doi: 10.1016/j.jalz.2014.03.011
12. Thambisetty M, Jeffrey Metter E, Yang A, Dolan H, Marano C, Zonderman AB, Troncoso JC, Zhou Y, Wong DF, Ferrucci L, Egan J, Resnick SM, O'Brien RJ (2013) Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 70, 1167-1172
13. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H (2009) Beta-Amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 35, 60-68
14. Heitner J, Dickson D (1997) Diabetics do not have increased Alzheimer-type pathology compared with agematched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49, 1306-1311
15. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403
16. Profenno LA, Porsteinsson AP, Faraone SV (2010) Metaanalysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67, 505-512
17. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der FlierW, Aalten P, Teunissen C, Barkhof F, BlennowK, Wolz R, Rueckert D, Verhey F, Visser PJ (2012) Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 33, 2272-2281
18. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid betaamyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389
19. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041
20. Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Ruther E, Wiltfang J (2012) Cerebrospinal fluid amyloid-beta 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 119, 805-813
21. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234
22. Sager MA, Hermann B, La Rue A (2005) Middle-Aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18, 245-249
23. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Associationworkgroupsondiagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
25. Aradillas-Garcia C, Rodriguez-Moran M, Garay-Sevilla ME, Malacara JM, Rascon-Pacheco RA, Guerrero-Romero F (2012) Distribution of the homeostasis model assessment of insulin resistance in Mexican children and adolescents. Eur J Endocrinol 166, 301-306
26. Singh Y, Garg MK, Tandon N, Marwaha RK (2013) A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol 5, 245-251
27. Yamada C, Mitsuhashi T, Hiratsuka N, Inabe F, Araida N, Takahashi E (2011) Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population. J Diabetes Investig 2, 373-376
28. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, De Francisco A, QuintelaAG(2013) Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13, 47
29. Johnson SC, La Rue A, Hermann BP, Xu G, Koscik RL, Jonaitis EM, Bendlin BB, Hogan KJ, Roses AD, Saunders AM, LutzMW, Asthana S, Green RC, SagerMA(2011) The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-Aged persons with APOE epsilon3/epsilon3 genotype. Alzheimers Dement 7, 456-465
30. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hagerstrom D, Wollmer P, Minthon L, Hansson O (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid betaamyloid 42: Across-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289
31. Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO (2013) Ratio of Abeta42/P-Tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep 3, 1339
32. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101, 3100-3105
33. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27, 13635-13648
34. De La Monte SM, TongM(2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88, 548-559
35. Stoothoff WH, Johnson GV (2005) Tau phosphorylation: Physiological and pathological consequences. Biochim Biophys Acta 1739, 280-297
36. Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, Walker DG, Lue L, Adem A, Sabbagh MN (2013) Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE epsilon.4 carrier status. Curr Alzheimer Res 10, 654-659
37. Profenno LA, Faraone SV (2008) Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population. Am J Med Genet B Neuropsychiatr Genet 147B, 822-829
38. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-Acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 44, 897-906
39. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-Amyloid in early AD. Neurology 70, 440-448
40. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903, 222-228
41. Craft S, Peskind E, SchwartzMW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168
42. Ong QR, Chan ES, Lim ML, Wong BS (2014) Expression of human apolipoprotein E4 reduces insulin-receptor substrate 1 expression and Akt phosphorylation in the ageing liver. FEBS Open Bio 4, 260-265
43. Burns JM, Honea RA, Vidoni ED, Hutfles LJ, Brooks WM, Swerdlow RH (2012) Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta 1822, 333-339
44. Burns JM, Donnelly JE, Anderson HS, Mayo MS, Spencer-Gardner L, Thomas G, Cronk BB, Haddad Z, Klima D, Hansen D, Brooks WM (2007) Peripheral insulin and brain structure in early Alzheimer disease. Neurology 69, 1094-1104
45. Marques-Vidal P, Mazoyer E, BongardV, Gourdy P, Ruidavets JB, Drouet L, Ferrieres J (2002) Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25, 1371-1377
46. Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB (2011) The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PloS One 6, e21041
47. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R (2003) Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26, 3320-3325
48. Standaert DG, Lee VM, Greenberg BD, Lowery DE, Trojanowski JQ (1991) Molecular features of hypothalamic plaques in Alzheimer's disease. Am J Pathol 139, 681-691
49. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802, 2-10
50. Swerdlow RH, Khan SM (2004) A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 63, 8-20
51. Kim JA, Wei Y, Sowers JR (2008) Role of mitochondrial dysfunction in insulin resistance. Circ Res 102, 401-414
52. Kandimalla RJ, Prabhakar S, WaniWY, Kaushal A, Gupta N, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD (2013) CSF p-Tau levels in the prediction of Alzheimer's disease. Biology Open 2, 1119-1124